Diabetes drugs must be targeted to ensure safety

Diabetes ResearchToday is World Diabetes Day – and there’s some great work being done at the Centenary Institute to understand and treat diabetes by Associate Professor Mark Gorrell and his team of liver researchers.

New research just published in the online journal PLOS ONE has confirmed that diabetes drugs and potential cancer therapies based on regulating the dipeptidyl peptidase (DPP) family of enzymes must be carefully targeted to avoid serious side effects, such as skin and intestinal damage.

Since the 1990’s Dr Mark Gorrell has been an advocate of drug targeting to safely treat diabetes. When enzyme-inhibiting drugs to treat diabetes were being developed, Dr Gorrell warned that care was needed to ensure the drugs targeted a specific enzyme, leaving other members of the enzyme family unaffected.

Thankfully, drug companies listened to this warning despite targeting being a disputed topic.

Continue reading

Fixing the body’s leaking pipes

Mirrx TherapeuticsCentenary’s discoveries lead to a commercial agreement to create drugs to fix leaking blood vessels.

Australian molecular biologists led by researchers at Centenary have made a synthetic compound that appears to allow them to control the leakiness of blood vessels. The work could lead to effective new drug treatments for strokes and tumours. Spinoffs may include an ability to reduce the side-effects of chemotherapy and inflammation.

Continue reading